Eli Lilly's 3-step strategy to dominate the $95 billion obesity market

Scientists at Eli Lilly are racing to develop new weight loss drugs that will be cheaper, stronger, or preserve more muscle mass.

Eli Lilly

• Eli Lilly has outpaced Ozempic-maker Novo Nordisk in the race to develop new incretin drugs.
• The company is set to capture 50% of the $95 billion obesity market by 2050.
• We got a glimpse into Eli Lilly's upcoming menu of metabolic drugs to treat obesity, preserve muscle, and more.

In sports, the best athletes compete against themselves.